Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study

Infectious Agents and Cancer

Dieter Hoffmann¹  Jürgen E. Gschwend³  Ulrike Protzer¹  Margitta Retz³  Hubert Kübler³  Michael Autenrieth³  Tobias Maurer³  Michael Straub³  Judith Seebach¹  Julia Slotta-Huspenina⁴  Florian Kurtz³  Thomas Horn³  Tibor Schuster²  Leonore Thümer¹  Sebastian C. Schmid⁵ 

[1] Department of Virology, Technische Universität/Helmholtz Zentrum München, Munich, Germany;Institute of Medical Statistics and Epidemiology, Technische Universität München, Munich, Germany;Department of Urology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany;Institute of Pathology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany;http://www.mriu.de

关键词: Polymerase chain reaction;    PCR;    HPV;    Papillomavirus;    Urothelial carcinoma;    Bladder cancer;   

Others  :  1228118
DOI  :  10.1186/s13027-015-0028-7

 received in 2015-02-23, accepted in 2015-08-24,  发布年份 2015

【 摘 要 】

Background

Previous investigations on the association of human papillomavirus (HPV) and human bladder cancer have led to conflicting results. The aim of this study was to determine if low and high risk HPV play a role in the etiology of superficial low grade and invasive high grade urothelial carcinoma of the bladder.

Methods

We prospectively collected tumor samples of urothelial carcinoma of the bladder from 109 patients treated with transurethral resection or cystectomy, with bladder tissue from transurethral resection of the prostate serving as control. Unfixed, frozen tumor samples were analyzed for the presence of 14 high risk HPV types using real time PCR. Additionally, all specimens were tested for 35 low risk HPV types with a conventional PCR using degenerate primers located in the L1 region. Six frozen samples of cervical carcinoma served as positive controls.

Results

We included 109 cases of bladder cancer with 41 superficial (pTa low grade) tumors, 56 invasive (pT1-T4) high grade tumors and 12 others (pTa high grade + pTis). We have not detected HPV-DNA in any sample (95 % Confidence Interval [CI] 0–3.3 %), superficial tumors (95 % CI 0–6.4 %) or in invasive tumors (95 % CI 0–8.6 %) with correct positive controls.

Conclusions

Using a broad, sensitive assay with prospectively collected specimens of a Central European population we could not detect HPV-DNA in any of the cases. Our results suggest that it is unlikely that HPV infections play a major role in the development of urothelial bladder cancer.

【 授权许可】

   
2015 Schmid et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Collaborators GBoDS: Institute for Health Metrics and Evaluation, University of Washington Global Burden of Disease Study 2010 (GBD 2010): Results by Cause 1990–2010 2010.
• [2]Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, Cordier S, Jockel KH, Lopez-Abente G, Tzonou A, Vineis P, et al.: The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001, 12(5):411-417.
• [3]Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A: Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009, 27(3):295-300.
• [4]Schmid SC, Schuster T, Horn T, Gschwend J, Treiber U, Weirich G: Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. Anticancer Res 2013, 33(9):3731-3737.
• [5]Boyle P: International Agency for Research on Cancer, World Health Organization: World cancer report 2008. IARC Press, Lyon; 2008.
• [6]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
• [7]Bernard HU, Burk RD, Chen Z, van Doorslaer K, Zur Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401(1):70-79.
• [8]Campo MS: Bovine papillomavirus and cancer. Vet J 1997, 154(3):175-188.
• [9]Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, Maclennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, et al.: p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol 2012, 25(11):1526-1533.
• [10]Ben Selma W, Ziadi S, Ben Gacem R, Amara K, Ksiaa F, Hachana M, Trimeche M: Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients. Pathol Res Pract 2010, 206(11):740-743.
• [11]Knowles MA: Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder. Urol Res 1992, 20(4):297-301.
• [12]Youshya S, Purdie K, Breuer J, Proby C, Sheaf MT, Oliver RT, Baithun S: Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005, 58(2):207-210.
• [13]Badawi H, Ahmed H, Ismail A, Diab M, Moubarak M, Badawy A, Saber M: Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medscape J Med 2008, 10(10):232.
• [14]Berrada N, Al-Bouzidi A, Ameur A, Abbar M, El-Mzibri M, Ameziane-El-Hassani R, Benbacer L, Khyatti M, Qmichou Z, Amzazi S, et al.: Human papillomavirus detection in Moroccan patients with bladder cancer. J Infect Dev Ctries 2013, 7(8):586-592.
• [15]Cai T, Mazzoli S, Meacci F, Nesi G, Geppetti P, Malossini G, Bartoletti R: Human papillomavirus and non-muscle invasive urothelial bladder cancer: potential relationship from a pilot study. Oncol Rep 2011, 25(2):485-489.
• [16]Newcombe RG: Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17(8):873-890.
• [17]Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006, 27(3):361-373.
• [18]Guimera N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, Hernandez-Suarez G, Bravo IG, Molijn A, Jenkins D, et al.: The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol 2013, 37(9):1299-1310.
• [19]Iwasaka T, Hayashi Y, Yokoyama M, Hara K, Matsuo N, Sugimori H: Hit and run’ oncogenesis by human papillomavirus type 18 DNA. Acta Obstet Gynecol Scand 1992, 71(3):219-223.
• [20]Jacobi C, Ayx I, Fritsche K, Piontek G, Hoffmann D, Weirich G, Knopf A: Potential impact of human papilloma virus on survival of basaloid squamous carcinoma of the head and neck. Oncotarget 2015, 6(5):3462-3470.
• [21]Pichler R, Borena W, Schafer G, Manzl C, Culig Z, List S, et al. Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot. World J Urol. 2015. [Epub ahead of print].
• [22]Jimenez-Pacheco A, Exposito-Ruiz M, Arrabal-Polo MA, Lopez-Luque AJ: Meta-analysis of studies analyzing the role of human papillomavirus in the development of bladder carcinoma. Korean J Urol 2012, 53(4):240-247.
• [23]Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M: Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011, 204(2):217-223.
• [24]Yavuzer D, Karadayi N, Salepci T, Baloglu H, Bilici A, Sakirahmet D: Role of human papillomavirus in the development of urothelial carcinoma. Med Oncol 2011, 28(3):919-923.
• [25]Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S: Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol 2014, 32(1):46 e19–27.